---
title: "Viatris gains as UBS upgrades to buy on outlook and pipeline"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/275354256.md"
description: "Shares of Viatris (VTRS) rose after UBS upgraded the stock to Buy from Neutral, increasing the price target from $8 to $11 per share. Analyst Ashwani Verma highlighted a positive growth outlook and a robust drug pipeline, adjusting estimates accordingly. He noted Viatris trades at a favorable valuation of 5x consensus EPS estimates for 2027. Overall, Wall Street maintains a bullish stance on Viatris, with an average analyst rating of Buy, while Seeking Alpha rates it as a Hold."
datetime: "2026-02-09T19:03:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275354256.md)
  - [en](https://longbridge.com/en/news/275354256.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275354256.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/275354256.md) | [繁體中文](https://longbridge.com/zh-HK/news/275354256.md)


# Viatris gains as UBS upgrades to buy on outlook and pipeline

Shares of Viatris (VTRS) traded higher on Monday after UBS upgraded the company to Buy from Neutral and lifted its price target to $11 from $8 per share, citing a promising growth outlook and a growing pipeline of drugs. Analyst Ashwani Verma hiked his estimates for the company, noting, “We layer in new product cycle pipeline & maintain potential c...

### 相关股票

- [iShares US Pharma (IHE.US)](https://longbridge.com/zh-CN/quote/IHE.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-CN/quote/IBBQ.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-CN/quote/ARKG.US.md)
- [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-CN/quote/XLV.US.md)
- [VG Health (VHT.US)](https://longbridge.com/zh-CN/quote/VHT.US.md)
- [iShares Global Healthcare (IXJ.US)](https://longbridge.com/zh-CN/quote/IXJ.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-CN/quote/IBB.US.md)
- [Viatris (VTRS.US)](https://longbridge.com/zh-CN/quote/VTRS.US.md)

## 相关资讯与研究

- [Viatris settles lawsuit over use of woman's 'immortal' cells to power drug research](https://longbridge.com/zh-CN/news/278908205.md)
- [A Look At Viatris (VTRS) Valuation After Earnings, 2026 Guidance And MR-141 FDA Review](https://longbridge.com/zh-CN/news/277640565.md)
- [Pfizer's eczema drug meets main goal in mid-stage trial, plans late-stage study](https://longbridge.com/zh-CN/news/278381816.md)
- [Vanda Advances NEREUS Launch With Direct-to-Consumer Strategy](https://longbridge.com/zh-CN/news/278644625.md)
- [EXCLUSIVE: Scienture Expands Reach For Opioid Overdose Treatment, With Deals Covering 60% Of US Institutional Market](https://longbridge.com/zh-CN/news/278715508.md)